The FMS-like tyrosine kinase 3 (FLT3) gene mutation is the most common genetic mutation in acute myeloid leukemia (AML) and is associated with poor prognosis. Various targeted inhibitors have been developed for FLT3 mutations and have shown promising clinical efficacy. However, the emergence of resistance poses new challenges for targeted therapy in AML. This article provides an overview of the pathological and prognostic role of FLT3 mutations in AML, the current research progress on commonly used FLT3 inhibitors (type I and type II), the mechanisms of FLT3 inhibitor resistance, and strategies for overcoming resistance.

（正）结肠代食管术（esophageal replacement with colon，ERC）被称作食管外科“皇冠上的明珠”，也是食管重建的最后一种选择。ERC 手术操作复杂，吻合口瘘等并发症发生率较高，一直没有得到广泛开展[1]。传统 ERC 手术常选择经右侧胸腹联合切口，手术创伤较大、术后恢复慢、术后肋间神经损伤等并发症较多，但随着胸腔镜微创技术的日益发展，我们使用胸腔镜微创技术游离胸腔食管并清扫纵隔淋巴结，开腹横结肠代食管行消化道重建，该技术可减少手术创伤、减轻术后疼痛，加速康复。本视频在于展示胸腔镜辅助食管癌根治横结肠代食管术手术入路、操作技巧。